NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
... internal clinical programs in hospital-associated infections and respiratory infections. provide ... blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has ... Aganocide compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. ...Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
... of Major Unmet Need, Including Hospital Acquired infections C. Difficile and MRSA Celtic Pharma ... will enter the clinic next year to treat infections caused by Clostridium difficile ("C. difficile"). ... than seen with existing drugs. C. difficile infections (CDIs) are a serious problem: the number of cases ...Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
... defenses to improve survival, reduce bacterial infections and suppress inflammation. IMX942 is a small, ... activity but can control the outcome of infections caused by a broad spectrum of pathogens; in ... studies it will be developed for control of infections in high risk patients in the hospital setting. ...Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
... effective treatments for drug resistant bacterial infections in the hospital and in the community." ... antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's ... lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For ...Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU
... will aid in the prevention and control of MRSA infections in healthcare settings resulting in better ... better patient care." Healthcare-associated infections (HAIs) caused by MRSA have recently become an ... aureus is responsible for many serious infections and is one of the most frequently isolated ...NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
... the treatment and prevention of a wide range of infections without causing resistance, reported today its ... to commercialize Aganocide compounds to treat infections of the eye, ear and sinus, and to develop the ... in-vivo in treating subcutaneous dermatophyte infections based on an established animal model. ...Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results
... cethromycin as a potential treatment for infections caused by community associated ... United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus ... the front-line treatments for respiratory tract infections such as CAP. As macrolide and ...Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
... the virus itself and eventually the opportunistic infections characteristic of AIDS." CCR5 is a ... destruction leaving them able fight opportunistic infections and HIV itself. About HIV/AIDS and CCR5 ... destroying the body's ability to fight infections and certain cancers resulting in AIDS (Acquired ...AdvanDx Receives FDA 510(k) Clearance for E. coli/P. aeruginosa PNA FISH(R)
... Outcomes for 100,000 Patients with Bloodstream infections WOBURN, Mass. and VEDBAEK, Denmark, Jan. 30 ... an estimated 100,000 patients develop bloodstream infections (BSI) due to Gram-negative pathogens such as E. ... aeruginosa . Patients afflicted by these serious infections spend an average of 5-24 days in the hospital, ...DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
... device to significantly reduce surgical site infections (SSIs) and potentially save the healthcare system ... technology designed to mitigate Surgical Site infections (SSIs) in spinal surgery. The technology will be ... to reduce and eliminate healthcare-associated infections (HAIs), one of the key areas being surgical site ...Advanced Life Sciences Announces Third Quarter 2008 Financial Results
... United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus ... the front-line treatments for respiratory tract infections such as CAP. As macrolide and ... for the treatment of respiratory tract infections including CAP. For more information, please visit ...Trius Awarded $28 Million Contract to Develop Novel Antibiotics
... approach to develop effective new drugs to treat infections caused by such deadly pathogens." "Our ... bacteria responsible for more common hospital infections for which there are few current treatment ... drugs for the treatment of infections caused by drug-resistant pathogens. The company's ...Transave, Inc. Secures $12.5 Million in New Financing
... Phase II program for the treatment of Pseudomonas infections in cystic fibrosis patients," said Tim Whitten, ... to evaluate the compound for treating Pseudomonas infections in patients with non-cystic fibrosis-related ... Agency (EMEA) for the treatment of Pseudomonas infections in patients with CF. About Transave, Inc. ...MIGENIX Reports First Quarter Fiscal 2009 Financial Results
... intravenous agent for treating serious infections caused by drug-resistant bacteria for which there ... the prevention of catheter-related infections (Phase III), the treatment of dermatological ... Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment ...Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
... may reduce incidence of surgical site infections and reduce post-operative cost and complications ... for prevention and treatment of surgical site infections (SSIs) in the United States. This agreement is ... for the treatment of localized, deep tissue infections and the prevention of SSIs in both hard and soft ...Arpida's iclaprim MAA Accepted for Review by EMEA
... a potent antibacterial that targets severe infections requiring hospital treatment, including those ... indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of ... AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 ...Advanced Life Sciences Announces Second Quarter 2008 Financial Results
... United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus ... the front-line treatments for respiratory tract infections such as CAP. As macrolide and ... for the treatment of respiratory tract infections including CAP. For more information, please visit ...Migenix averts proxy contest; reaches agreement with DJohnson holdings
... the prevention of catheter-related infections (Phase III), the treatment of dermatological ... Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis ...Notice of MIGENIX General Meeting of Shareholders
... the prevention of catheter-related infections (Phase III), the treatment of dermatological ... Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis ...MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification
... the prevention of catheter-related infections (Phase III), the treatment of dermatological ... Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis ...Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
... used to treat a variety of infections and is the generic equivalent of Roche's ... Ceftriaxone for injection, USP, is indicated for infections of the lower respiratory tract, urinary tract, ... may also reduce the incidence of postoperative infections is used as a surgical prophylaxis ...MIGENIX Corporate Update and Requisition of Special Meeting
... the prevention of catheter-related infections (end of Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of ... the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis ...Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
... and E7, that are made in higher amounts when HPV infections progress toward cervical cancer. Gen-Probe ... DNA identifies women who are infected, but HPV infections are common and many resolve without causing ... some point in their lives, the majority of these infections are transient and resolve without any ...Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
... the prevention of catheter-related infections (end of Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of ... the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis ...